Approval summary: cetuximab in combination with cisplatin or carboplatin and 5‐fluorouracil for the first‐line treatment of patients with recurrent locoregional or …
MH Cohen, H Chen, S Shord, C Fuchs, K He… - The …, 2013 - academic.oup.com
Abstract Learning Objectives Compare survival outcomes among patients with SCCHN
treated with a platinum/5‐FU regimen with and without cetuximab. Compare adverse event …
treated with a platinum/5‐FU regimen with and without cetuximab. Compare adverse event …
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
Cetuximab is typically administered on a weekly schedule for patients with recurrent or
metastatic head and neck squamous cell cancer (HNSCC). This study explores cetuximab …
metastatic head and neck squamous cell cancer (HNSCC). This study explores cetuximab …
[HTML][HTML] The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck
R Mehra, RB Cohen, BA Burtness - Clinical advances in …, 2008 - ncbi.nlm.nih.gov
Squamous cell carcinoma of the head and neck (HNSCC) while curable in many cases with
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …
[HTML][HTML] First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck …
Y Guo, Y Luo, Q Zhang, X Huang, Z Li, L Shen… - European Journal of …, 2021 - Elsevier
Background The EXTREME regimen (chemotherapy [CT; cisplatin/carboplatin and 5-
fluorouracil]) plus cetuximab is a standard-of-care first-line (1L) treatment for patients with …
fluorouracil]) plus cetuximab is a standard-of-care first-line (1L) treatment for patients with …
A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
K Nakano, S Marshall, S Taira, Y Sato, J Tomomatsu… - Oral oncology, 2017 - Elsevier
Background The effectiveness of the combination chemotherapy of weekly paclitaxel and
cetuximab has not yet been compared to that of the current standard regimen, EXTREME …
cetuximab has not yet been compared to that of the current standard regimen, EXTREME …
[HTML][HTML] Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic …
M Tahara, N Kiyota, T Yokota, Y Hasegawa, K Muro… - Annals of …, 2018 - Elsevier
Background The standard of care for first-line treatment of recurrent and/or metastatic
squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with …
squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with …
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between …
H Sato, K Tsukahara, I Okamoto, Y Katsube… - Acta Oto …, 2019 - Taylor & Francis
Background: Combination therapy consisting of a platinum agent, 5-fluorouracil and
cetuximab (EXTREME regimen) is recommended for recurrent or metastatic squamous cell …
cetuximab (EXTREME regimen) is recommended for recurrent or metastatic squamous cell …
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced …
D Soulieres, JL Aguilar, E Chen, K Misiukiewicz… - BMC cancer, 2016 - Springer
Background Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients
B Jiménez, JM Trigo, BI Pajares, MI Sáez, C Quero… - Oral oncology, 2013 - Elsevier
INTRODUCTION: The addition of cetuximab to weekly paclitaxel has demonstrated high
efficacy in the first-line treatment of patients with recurrent/metastatic squamous cell …
efficacy in the first-line treatment of patients with recurrent/metastatic squamous cell …
Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance
E Muraro, G Fanetti, V Lupato, V Giacomarra… - Critical Reviews in …, 2021 - Elsevier
Since its introduction, the use of cetuximab in the treatment of head and neck squamous cell
carcinoma (HNSCC) has experienced an evolution. Currently, cetuximab associated with …
carcinoma (HNSCC) has experienced an evolution. Currently, cetuximab associated with …